Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis

British Journal of Psychiatry

Volumn 204, Issue 6, 2014, Pages 448-453

  Sara, Grant E ^a   Burgess, Philip M ^b   Malhi, Gin S ^c   Whiteford, Harvey A ^b   Hall, Wayne C ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BRIEF PSYCHOTIC DISORDER; CANNABIS ADDICTION; COMORBIDITY; DRUG ABUSE; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; AMPHETAMINE-RELATED DISORDERS; EPIDEMIOLOGY; HUMANS; MARIJUANA ABUSE; NEW SOUTH WALES; PATIENT READMISSION; PSYCHOTIC DISORDERS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NEW SOUTH WALES; PATIENT READMISSION; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84899820189     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.135145     Document Type: Article

References (41)

1. Álvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 2011; 37: 619-30.
2. Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011; 37: 631-9.
3. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, Le Quach P, et al. Course of illness in a sample of 265 patients with first-episode psychosis - five-year follow-up of the Danish OPUS trial. Schizophr Res 2009; 107: 173-8.
4. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 2006; 81: 145-50.
5. Sara G, Burgess P, Malhi G, Whiteford H, Hall W. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res 2013; 147: 216-22.
6. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry 2006; 189: 137-43.
7. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, et al. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108: 84-97.
8. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev 2010; 29: 456-61.
9. Gleeson JFM, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 2010; 119: 79-88.
10. Centre for Epidemiology and Evidence. Health Statistics New South Wales: NSW Population. NSW Ministry of Health, 2012.
11. Yung AR, McGorry PD. Prediction of psychosis: setting the stage. Br J Psychiatry 2007; 191 (suppl 51): s1-8.
12. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. WHO, 1992.
13. Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry 1998; 172: 11-8.
14. Burgess P, Trauer T, Coombs T, McKay R, Pirkis J. What does 'clinical significance' mean in the context of the Health of the Nation Outcome Scales? Australas Psychiatry 2009; 17: 141-8.
15. Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med 2008; 38: 1585-93.
16. Addington DE, Beck C, Wang J, Adams B, Pryce C, Zhu H, et al. Predictors of admission in first-episode psychosis: developing a risk adjustment model for service comparisons. Psychiatr Serv 2010; 61: 483-8.
17. González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011; 37: 631-9.
18. Addington J, Addington D. Effect of substance misuse in early psychosis. Br J Psychiatry 1998; 172 (suppl 33): 134-6.
19. Degenhardt L, Roxburgh A, McKetin R. Hospital separations for cannabisand methamphetamine-related psychotic episodes in Australia. Med J Aust 2007; 186: 342-5.
20. Curran C, Byrappa N, Mcbride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196-204.
21. Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 2009; 190 (suppl 4): s22-5.
22. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck Jr PE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64: 57-64.
23. Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 2009; 113: 129-37.
24. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141-8.
25. Gupta P, Mullin K, Nielssen O, Harris A, Large M. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Aust NZ J Psychiatry 2013; 47: 524-37.
26. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res 2011; 128: 111-6.
27. Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012; 38: 316-30.
28. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23: 717-34.
29. Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berlin) 2009; 205: 45-52.
30. Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci 2009; 3: 53.
31. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358-67.
32. Crebbin K, Mitford E, Paxton R, Turkington D. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 710-5.
33. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187: 510-5.
34. Durbin J, Lin E, Layne C, Teed M. Is readmission a valid indicator of the quality of inpatient psychiatric care? J Behav Health Serv Res 2007; 34: 137-50.
35. Sipos A, Harrison G, Gunnell D, Amin S, Singh SP. Patterns and predictors of hospitalisation in first-episode psychosis. Prospective cohort study. Br J Psychiatry 2001; 178: 518-23.
36. Petersen L, Jeppesen P, Thorup A, Abel M-B, Øhlenschlæger J, Christensen TØ, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005; 331: 602-5.
37. Wade D, Harrigan S, Harris MG, Edwards J, McGorry PD. Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. Aust NZ J Psychiatry 2006; 40: 429-36.
38. Compton MT, Gordon TL, Goulding SM, Esterberg ML, Carter T, Leiner AS, et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. J Clin Psychiatry 2011; 72: 225-32.
39. Warner R. Recovery from schizophrenia and the recovery model. Curr Opin Psychiatry 2009; 22: 374-80.
40. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011; 24: 114-21.
41. Stowkowy J, Addington D, Liu L, Hollowell B, Addington J. Predictors of disengagement from treatment in an early psychosis program. Schizophr Res 2012; 136: 7-12.